Disofenin

Disofenin

SCHEMBL135703

CC(C)c1cccc(C(C)C)c1NC(=O)CN(CC(=O)O)CC(=O)O

nearest known ligand 0.64

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.64
ALOX15 P16050 1/20 0.64
TSHR P16473 1/20 0.64
CYP2C19 P33261 1/20 0.64
HIF1A Q16665 1/20 0.64
SMN1; SMN2 Q16637 1/20 0.60
SOAT1 P35610 3/20 0.53
SOAT2 O75908 2/20 0.53
KMT2A Q03164 5/20 0.53
LMNA P02545 4/20 0.53
MEN1 O00255 4/20 0.52
DRD3 P35462 1/20 0.48
MAPT P10636 2/20 0.48
ALDH1A1 P00352 1/20 0.48
CYP3A4 P08684 1/20 0.48
MAPK1 P28482 1/20 0.48
MC4R P32245 1/20 0.48
SCN4A P35499 1/20 0.48
MC3R P41968 1/20 0.48
HTR3A P46098 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Disofenin SCHEMBL29687882 0.98 TDP1 (0.62) TDP1ALOX15TSHRCYP2C19HIF1A
SCHEMBL9679857 0.90 SOAT2 (0.57) TDP1ALOX15TSHRCYP2C19HIF1A
SCHEMBL9491944 0.86 LMNA (0.65) TDP1ALOX15TSHRCYP2C19HIF1A
SCHEMBL9679656 0.84 SOAT2 (0.60) TDP1SMN1; SMN2SOAT1SOAT2KMT2A
SCHEMBL20763994 0.83 SMN1; SMN2 (0.66) TDP1SMN1; SMN2SOAT1SOAT2KMT2A
SCHEMBL2148218 0.82 SMN1; SMN2 (0.70) TDP1SMN1; SMN2SOAT1SOAT2KMT2A
Disofenin SCHEMBL7825569 0.81 ALOX15 (0.45) TDP1ALOX15TSHRCYP2C19HIF1A
Benzene SCHEMBL9851028 0.81 SMN1; SMN2 (0.68) TDP1SMN1; SMN2SOAT1SOAT2KMT2A
SCHEMBL9843936 0.80 SMN1; SMN2 (0.77) TDP1SMN1; SMN2SOAT1SOAT2KMT2A
Lidofenin SCHEMBL214472 0.80 MAPT (0.73) TDP1ALOX15TSHRCYP2C19HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260137621-A1 ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS DIASOME PHARMACEUTICALS INC (US) 2026-05-21 US claimed
US-20250288521-A1 ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS DIASOME PHARMACEUTICALS INC (US) 2025-09-18 US claimed
US-20250121100-A1 COMPOSITION AND METHOD FOR DIAGNOSTIC IMAGING SUNTEC MEDICAL INC (US) 2025-04-17 US claimed
CN-119698306-A Compositions and methods for diagnostic imaging 欣扬生医股份有限公司 2025-03-25 CN claimed
US-20250091013-A1 Three-Compartment Bipolar Membrane Electrodialysis Of Salts Of Amino Acids MONSANTO TECHNOLOGY LLC 2025-03-20 US claimed
US-20240158423-A1 TWO-COMPARTMENT BIPOLAR MEMBRANE ELECTRODIALYSIS OF SALTS OF AMINO ACIDS MONSANTO TECHNOLOGY LLC 2024-05-16 US claimed
EP-4301763-A1 TWO-COMPARTMENT BIPOLAR MEMBRANE ELECTRODIALYSIS OF SALTS OF AMINO ACIDS Monsanto Technology LLC (US) 2024-01-10 EP claimed
US-20230201386-A1 PRODUCING RADIOPHARMACEUTICAL COLD KITS WITHOUT LYOPHILIZATION THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA 2023-06-29 US claimed
WO-2022187407-A1 TWO-COMPARTMENT BIPOLAR MEMBRANE ELECTRODIALYSIS OF SALTS OF AMINO ACIDS MONSANTO TECHNOLOGY LLC (US) 2022-09-09 WO claimed
CN-114366825-A Response type isotope targeting drug and preparation method and application thereof 中国科学院宁波材料技术与工程研究所慈溪生物医学工程研究所 2022-04-19 CN claimed
EP-1087753-A1 TARGETED LIPOSOMAL DRUG DELIVERY SYSTEM SDG, Inc. (US) 2001-04-04 EP claimed
CN-1264310-A Polymer based pharmaceutical compositions for targeted delivery of biologically active agents SDG INC (US) 2000-08-23 CN claimed
EP-1005327-A1 TARGETED LIPOSOMAL CONSTRUCTS FOR DIAGNOSTIC AND THERAPEUTIC USES SDG, INC. (US) 2000-06-07 EP claimed
US-6063400-A CARRIER; DIAGNOSTIC OR THERAPEUTIC AGENT AND SEQUESTERING AGENT SDG, INC. (US) 2000-05-16 US claimed
WO-1999059545-A9 TARGETED LIPOSOMAL DRUG DELIVERY SYSTEM SDG INC (US) 2000-04-27 WO claimed
WO-1999059545-A1 TARGETED LIPOSOMAL DRUG DELIVERY SYSTEM SDG, INC. (US) 1999-11-25 WO claimed
WO-1999001110-A1 TARGETED LIPOSOMAL CONSTRUCTS FOR DIAGNOSTIC AND THERAPEUTIC USES SDG, INC. (US) 1999-01-14 WO claimed
US-5225182-A For specific organ delivery SHARMA YASH P (US) 1993-07-06 US claimed
EP-0166746-B1 PREPARATION OF ?99M TC RADIOPHARMACEUTICALS THE COMMONWEALTH OF AUSTRALIA (AU) 1991-04-24 EP claimed
WO-1985003063-A1 PREPARATION OF 99mTC RADIOPHARMACEUTICALS THE COMMONWEALTH OF AUSTRALIA (AU) 1985-07-18 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250288521-A1 ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS FABP2, FABP1, FABP6 TDP1 4819/4885ALOX15 414/4885TSHR 161/4885
US-20250091013-A1 Three-Compartment Bipolar Membrane Electrodialysis Of Salts Of Amino Acids SLC1A3, SLC1A2, SLC1A1 TDP1 3832/4885ALOX15 4491/4885TSHR 1514/4885
US-20260137621-A1 ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS FABP2, FABP1, SGMS2 TDP1 4755/4885ALOX15 3077/4885TSHR 367/4885
US-20250121100-A1 COMPOSITION AND METHOD FOR DIAGNOSTIC IMAGING ABCB4, C5, APOB TDP1 3106/4885ALOX15 2592/4885TSHR 4788/4885
US-20240158423-A1 TWO-COMPARTMENT BIPOLAR MEMBRANE ELECTRODIALYSIS OF SALTS OF AMINO ACIDS SLC1A2, SLC5A11, SLC3A2 TDP1 2236/4885ALOX15 4660/4885TSHR 2427/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.